Literature DB >> 22968851

Left circumflex coronary artery is protected against no-reflow phenomenon following percutaneous coronary intervention for coronary artery disease.

Toshiyuki Nagai1, Takuro Hirano, Mayumi Tsunoda, Haruhiko Hosaka, Yoshikazu Kishino, Takaharu Katayama, Keisuke Matsumura, Takashi Miyagawa, Shun Kohsaka, Toshihisa Anzai, Keiichi Fukuda, Masahiro Suzuki.   

Abstract

Despite the positive impact of percutaneous coronary intervention (PCI) on reducing mortality, a small percentage of patients experience poor myocardial reperfusion following PCI. However, factors associated with no-reflow remain unclear. We investigated clinical factors associated with no-reflow following PCI for coronary artery disease (CAD). We retrospectively analyzed 1622 consecutive CAD patients who underwent PCI over a 5-year period at our institution. Patients were divided into two groups according to the presence (n = 31) or absence (n = 1591) of no-reflow, defined as Thrombolysis in Myocardial Infarction flow grade <3 after PCI. No significant differences in patient characteristics or PCI strategy were seen between the no-reflow and normal flow groups. The incidence of no-reflow was significantly lower in the left circumflex artery (LCx) than in the left anterior descending artery (LAD) (P = 0.0015), with no differences in characteristics or PCI strategy between these two target vessels. Multivariate analysis revealed that involvement of the LCx was an independent protective factor against no-reflow (odds ratio 0.14, 95 % confidence interval 0.02-0.98, P = 0.044). In conclusion, LCx as the target vessel was protective against no-reflow compared with LAD following PCI for CAD. Our results suggest that embolic protection devices may be unnecessary in CAD patients with involvement of LCx.

Entities:  

Mesh:

Year:  2012        PMID: 22968851     DOI: 10.1007/s00380-012-0281-2

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  36 in total

1.  Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention.

Authors:  Ronen Jaffe; Thierry Charron; Geoffrey Puley; Alexander Dick; Bradley H Strauss
Journal:  Circulation       Date:  2008-06-17       Impact factor: 29.690

2.  Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin.

Authors:  B M Kaplan; K H Benzuly; J W Kinn; T R Bowers; F V Tilli; C L Grines; W W O'Neill; R D Safian
Journal:  Cathet Cardiovasc Diagn       Date:  1996-10

3.  Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience.

Authors:  W B Hillegass; N A Dean; L Liao; R G Rhinehart; P R Myers
Journal:  J Am Coll Cardiol       Date:  2001-04       Impact factor: 24.094

Review 4.  No-reflow phenomenon and prognosis in patients with acute myocardial infarction.

Authors:  Hiroshi Ito
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2006-09

5.  Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction.

Authors:  Vincenzo Pasceri; Christian Pristipino; Francesco Pelliccia; Antonino Granatelli; Giulio Speciale; Adriana Roncella; Bruno Pironi; Michele Capasso; Giuseppe Richichi
Journal:  Am J Cardiol       Date:  2005-06-01       Impact factor: 2.778

6.  Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial.

Authors:  Gregg W Stone; John Webb; David A Cox; Bruce R Brodie; Mansoor Qureshi; Anna Kalynych; Mark Turco; Heinz P Schultheiss; Daniel Dulas; Barry D Rutherford; David Antoniucci; Mitchell W Krucoff; Raymond J Gibbons; Denise Jones; Alexandra J Lansky; Roxana Mehran
Journal:  JAMA       Date:  2005-03-02       Impact factor: 56.272

7.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

8.  Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: role of inhibitory effect on reactive oxygen species formation.

Authors:  Hirotsugu Ono; Tomohiro Osanai; Hiroshi Ishizaka; Hiroyuki Hanada; Takaatsu Kamada; Hiroyuki Onodera; Norio Fujita; Shingo Sasaki; Toshiro Matsunaga; Ken Okumura
Journal:  Am Heart J       Date:  2004-10       Impact factor: 4.749

9.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

10.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

Authors: 
Journal:  Lancet       Date:  1998-07-11       Impact factor: 79.321

View more
  3 in total

1.  A simple and rapid method for identification of lesions at high risk for the no-reflow phenomenon immediately before elective coronary stent implantation.

Authors:  Akira Suda; Shigeto Namiuchi; Tomohiro Kawaguchi; Taro Nihei; Toru Takii; Kenya Saji; Tadashi Sugie; Atsushi Kato; Hiroaki Shimokawa
Journal:  Heart Vessels       Date:  2016-03-02       Impact factor: 2.037

2.  To kiss or not to kiss? Impact of final kissing-balloon inflation on early and long-term results of percutaneous coronary intervention for bifurcation lesions.

Authors:  Giuseppe Biondi-Zoccai; Imad Sheiban; Stefano De Servi; Corrado Tamburino; Giuseppe Sangiorgi; Enrico Romagnoli
Journal:  Heart Vessels       Date:  2014-11       Impact factor: 2.037

3.  TLR3 and TLR4 as potential clinically biomarkers of cardiovascular risk in coronary artery disease (CAD) patients.

Authors:  Liang Shao; Ping Zhang; Yong Zhang; Qun Lu; Aiqun Ma
Journal:  Heart Vessels       Date:  2013-10-22       Impact factor: 2.037

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.